# A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

> **NCT07144280** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 680 (estimated)

## Conditions studied

- Non-small Cell Carcinoma
- Non-Small Cell Lung Cancer Metastatic
- Non-Small Cell Lung Carcinoma

## Interventions

- **DRUG:** PF-08046054
- **DRUG:** Docetaxel monotherapy

## Key facts

- **NCT ID:** NCT07144280
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-29
- **Primary completion:** 2028-03-10
- **Final completion:** 2032-03-10
- **Target enrollment:** 680 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07144280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07144280, "A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07144280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*